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Conclusions. Tumour regression grade has a signiﬁcant impact on survival outcomes, which were lower in patients with poor
down-staging after neoadjuvant treatment. The use of a standardized system to evaluate tumour response in rectal cancer can
allow for comparisons between different institutions and can identify patients at worse prognosis to be treated with adjuvant
therapy. However, these results need further analysis with prospective studies.
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Background. Squamous cell cancer of the anus is an uncommon malignancy. The idea of organ preservation emerged following the
discovery of a high rates of complete response to combined chemoradiation prior to abdominal–perineal resection. Radiotherapy,
with concomitant chemotherapy for advanced tumours, is now the standard ﬁrst-line treatment for anal carcinoma.
Aim. The aim of this study was to retrospectively evaluate clinical characteristics, local control, and acute toxicity of patients
with anal canal carcinoma treated with radiation therapy. Methods: From 2004 to 2011, 16 patients with good performance status
(Karnofsky Performance status ≥70) were treated with radiation therapy at a single institution. The median age was 64 years
(range, 33–82 years). The TNM classiﬁcation was as follows: 2 stage I, 4 stage II, 4 stage III, 2 unknown and 4 recurrences. Patients
received either radiochemotherapy (N=12) or radiotherapy alone (N=6) consisting of a median delivered dose of 50Gy. Toxicity
was evaluated using the Radiation Therapy Oncology Group scale.
Results. With a median follow-up of 16 months (range, 23–47), there were 6 relapses (2 both regional and distant and 4 both
local-regional and distant). The main symptom at diagnosis was pain in the anal area (N=8) followed by rectal bleeding (N=6).
The most common acute grade 3 complication was radiation mucositis, which occurred in 6 cases (38%). In addition, ﬁve patients
experienced grade 2 acute proctitis and 5 grade 3 after radiation therapy. Only 3 patients showed grade 3 acute dermatitis being
grade 2 in 7 patients.
Conclusions. Radiation therapy appears to be an effective and well tolerated treatment for anal carcinoma offering both high local
tumor control and anal sphincter preservation.
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Introduction. The current treatment of anal canal cancer is concurrent radiotherapy and chemotherapy. Our new goal is to achieve
better local control rates without increasing secondary effects. The IMRT is a new path to follow to achieve this goal. OBJECTIVE:
To evaluate the outcomes and toxicity of patients with anal canal carcinoma treated with IMRT and simultaneous integrated
boost.
Method and materials. 9 patients with biopsy proved squamous cell carcinoma treated with IMRT with simultaneous integrated
boost were analyzed. Six of them were simulated with PET-CT, and all of them received concomitant chemotherapy. Treatment
volumes were macroscopic tumor and suspected malignant nodes as GTV, pelvic lymph nodes at risk including inguinal regions
as CTV; PTVs was created expanding CTVs by 0.5 cm. Dose schedule was 50.4Gy at 1.8Gy/day to tumor and lymph nodes at risk
and 60.48Gy in an integrated boost of 2.16Gy to visible tumor and malignant suspected lymph nodes. Treatment was completed
in 28 fractions. Megavoltage ConeBeam CT IGRT was performed in all patient.
Results. The mean age was 62 years (43–87). All patients received concomitant chemotherapy with mitomycin C and 5FU, except
an elderly patient who was treated with Xeloda Two patients had acute genitourinary toxicity (ctcae v3) GII. Six patients had
grade II skin toxicity, no toxicity greater than G-III was found. One patient developed G-III proctitis two years after treatment
completion and were treated with argon laser. One patient had a local recurrence one year after treatment and was surgically
rescued. Histopathological analysis showed the presence of adenocarcinoma instead of the initially proved squamous histology.
Conclusion. IMRT is well tolerated in patients with anal cancer and the use of integrated boost, do not seems to increase the acute
or chronic toxicity compared to historical series.
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